NeuroThera Labs Inc.
Share Statistics
As of July 31, 2025, NeuroThera Labs Inc. has 57.79M shares outstanding.
| Shares Outstanding | 57.79M |
Financial Position
As of July 31, 2025, NeuroThera Labs Inc. maintains a current ratio of 6.70, meaning it holds 6.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.70 |
| Quick Ratio | 6.70 |
Financial Efficiency
Over the twelve months ended July 31, 2025, NeuroThera Labs Inc. posted a negative return on equity (ROE) of -22.64, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -20.32, reflecting losses generated across the asset base.
| Return on Equity (ROE) | -22.64 |
| Return on Assets (ROA) | -20.32 |
Income Statement
CADOver the twelve months ended July 31, 2025, NeuroThera Labs Inc. generated - - in revenue and converted that into -189,228.51 in net income, yielding earnings per share of -0.01. EBITDA reached -189,124.01, while operating income came in at -189,124.01.
| Operating Income | -189,124.01 |
| Pretax Income | -189,228.51 |
| Net Income | -189,228.51 |
| EBITDA | -189,124.01 |
| EBIT | -189,124.01 |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
CADThese figures are as of July 31, 2025. Total book value stands at 893,365.22, with working capital of 893,365.22 providing operational flexibility.
| Cash & Cash Equivalents | 1.05M |
| Net Debt | -1.05M |
| Equity (Book Value) | 893,365.22 |
| Book Value Per Share | 0.02 |
| Working Capital | 893,365.22 |
Cash Flow
CADNeuroThera Labs Inc. produced -58,516.72 in operating cash flow over the twelve months ended July 31, 2025.
| Operating Cash Flow | -58,516.72 |
| Free Cash Flow | -58,516.72 |